Phibro Animal Health Corporation (PAHC) is a Healthcare stock trading at $36.30 (as of 2026-08-21), with a market capitalization of $1.49B and a trailing P/E of 15.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Phibro Animal Health Corporation develops, manufactures, and supplies animal health and mineral nutrition products for livestock, with a focus on the United States. It operates through Animal Health, Mineral Nutrition, and Performance Products, serving markets such as poultry, swine, beef and dairy cattle, and aquaculture with items including antibacterials, anticoccidials, anthelmintics, anti-bloat products, specialty nutrition products, and vaccines.
Phibro Animal Health develops, manufactures, and markets animal health and mineral nutrition products for livestock, making money through net sales of those products across three segments.
The company generates profit by selling animal health and mineral nutrition products, with results driven by how much net sales come from its three reportable segments (especially Animal Health).
| Animal Health | $0.3B |
| Mineral Nutrition | $0.1B |
| Performance Products | $0.0B |
Business quality (Solid): Segment net sales are provided for Animal Health, Mineral Nutrition, and Performance Products, but no operating KPIs are included in the provided data, so it is harder to pinpoint the main operational driver beyond segment sales and margins.
Valuation: At 14× earnings, PAHC trades 19% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $36.30 |
| Market Cap | $1.49B |
| P/E Ratio | 15.6 |
| EV / EBITDA | 8.9 |
| Price / Book | 4.12 |
| Price / Sales | 0.99 |
| FCF Yield | 0.9% |
| DCF Value (model) | $53.85 |
| DCF Upside vs Price | 48.3% |
| Revenue (TTM) | $1.30B |
| Net Margin | 3.7% |
| Revenue Growth (YoY) | 10.3% |
| EPS Growth (YoY) | 13.5% |
| FCF Growth (YoY) | -97.5% |
| Altman Z-Score | 2.78 (grey) |
| Stock P/E | 15.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -28.0% |
| vs Industry | -8.9% |
| Top Institutional Holder | BlackRock, Inc. ($179.97M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jack Clifford Bendheim |
| Employees | 1,940 |
| Country | US |
| IPO Date | 2014-04-11 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.